Literature DB >> 32845401

Endoscopic ultrasound: a powerful tool to modify treatment algorithms in opioid-induced achalasia.

Arielle M Lee1,2, Josefin Holmgren3, Ryan C Broderick3, Joslin N Cheverie3, Bryan J Sandler3, Garth R Jacobsen3, Wilson T Kwong4, David C Kunkel4, Santiago Horgan3.   

Abstract

BACKGROUND: Opioid use in the U.S. has increased dramatically over the last 15 years, recently being declared a public health emergency. Opioid use is associated with esophageal dysmotility lending to a confusing clinical picture compared to true achalasia. Patients exhibit symptoms and elicit diagnostic results consistent with esophageal motility disorders, in particular type III achalasia. Modified therapeutic strategies and outcomes become challenging. Differentiating true achalasia from opioid-induced achalasia is critical. Conventional surgical interventions, i.e., myotomy, are ineffective in the absence of true achalasia. We assess the utility of esophageal muscle layer mapping with endoscopic ultrasound (EUS) in distinguishing primary from opioid-induced achalasia.
METHODS: From 2016 to 2019, patients with abnormal manometry and suspected achalasia underwent esophagogastroduodenoscopy and EUS mapping of esophageal round muscle layer thickness. Maximum round layer thickness and length of round muscle layer thickness > 1.8 mm were collected and compared between opioid users and non-opioid users using Wilcoxon Rank sum test.
RESULTS: 45 patients were included: 12 opioid users, 33 non-opioid users. Mean age 56.8 years (range 24-93), 53.3% male patients. Mean BMI in the opioid-induced achalasia group was 30.2 kg/m2, mean BMI in the primary achalasia group 26.8 kg/m2 (p = 0.11). In comparing endoscopic maximum round layer thickness between groups, non-opioid patients had a thicker round muscle layer (2.7 mm vs 1.8 mm, p = 0.05). Length of abnormally thickened esophageal muscle (greater than 1.8 mm) also differed between the two groups; patients on opioids had a shorter length of thickening (4.0 cm vs 0.0 cm, p = 0.04). Intervention rate was higher in the non-opioid group (p = 0.79). Of the patients that underwent therapeutic intervention, symptom resolution was higher in the non-opioid group (p = 0.002), while re-intervention post-procedure for persistent symptomatology was elevated in the opioid subset (p = 0.06). Patients in the opioid group were less likely to undergo invasive treatment (Heller). As of 2017 all interventions in the opioid group have been endoscopic.
CONCLUSION: Endoscopic ultrasound is an essential tool that has improved our treatment algorithm for suspected achalasia in patients with chronic opioid usage. Incorporation of EUS findings into treatment approach may prevent unnecessary surgery in opioid users.

Entities:  

Keywords:  Achalasia; Endoscopic ultrasound; Esophageal dysmotility; Foregut; Motility

Year:  2020        PMID: 32845401     DOI: 10.1007/s00464-020-07882-0

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  33 in total

1.  Differences in the prevalence and severity of side effects based on type of analgesic prescription in patients with chronic cancer pain.

Authors:  Patrice Villars; Marylin Dodd; Claudia West; Theresa Koetters; Steven M Paul; Karen Schumacher; Debu Tripathy; Peter Koo; Christine Miaskowski
Journal:  J Pain Symptom Manage       Date:  2007-01       Impact factor: 3.612

Review 2.  Treatment of opioid-induced gut dysfunction.

Authors:  Peter Holzer
Journal:  Expert Opin Investig Drugs       Date:  2007-02       Impact factor: 6.206

Review 3.  Incidence, prevalence, and management of opioid bowel dysfunction.

Authors:  M Pappagallo
Journal:  Am J Surg       Date:  2001-11       Impact factor: 2.565

4.  Opiate-induced oesophageal dysmotility.

Authors:  R E Kraichely; A S Arora; J A Murray
Journal:  Aliment Pharmacol Ther       Date:  2009-12-08       Impact factor: 8.171

5.  Opioid-Induced Esophageal Dysfunction (OIED) in Patients on Chronic Opioids.

Authors:  Shiva K Ratuapli; Michael D Crowell; John K DiBaise; Marcelo F Vela; Francisco C Ramirez; George E Burdick; Brian E Lacy; Joseph A Murray
Journal:  Am J Gastroenterol       Date:  2015-06-02       Impact factor: 10.864

Review 6.  Reduction in pain: Is it worth the gain? The effect of opioids on the GI tract.

Authors:  J Nee; V Rangan; A Lembo
Journal:  Neurogastroenterol Motil       Date:  2018-05       Impact factor: 3.598

Review 7.  America's Opioid Epidemic: Supply and Demand Considerations.

Authors:  David J Clark; Mark A Schumacher
Journal:  Anesth Analg       Date:  2017-11       Impact factor: 5.108

Review 8.  Chronic Opioid Use After Surgery: Implications for Perioperative Management in the Face of the Opioid Epidemic.

Authors:  Jennifer M Hah; Brian T Bateman; John Ratliff; Catherine Curtin; Eric Sun
Journal:  Anesth Analg       Date:  2017-11       Impact factor: 5.108

9.  Effects of Amitriptyline and Escitalopram on Sleep and Mood in Patients With Functional Dyspepsia.

Authors:  Linda M Herrick; Michael Camilleri; Cathy D Schleck; Alan R Zinsmeister; Yuri A Saito; Nicholas J Talley
Journal:  Clin Gastroenterol Hepatol       Date:  2017-12-01       Impact factor: 11.382

10.  Drug and Opioid-Involved Overdose Deaths - United States, 2013-2017.

Authors:  Lawrence Scholl; Puja Seth; Mbabazi Kariisa; Nana Wilson; Grant Baldwin
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2018-01-04       Impact factor: 17.586

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.